English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 15 December 2020, 09:00 HKT/SGT
Share:
    

Source: Azooka Labs
Azooka Labs unveils Safe MTM to Store COVID-19 Samples at Room Temperature for up to a week
Molecular Transport Medium at the price of VTM

BANGALORE, INDIA, Dec 15, 2020 - (ACN Newswire) - Azooka Labs, a leading safe fluorophore company with specialization in Molecular Biology products, reveals its first range of novel COVID-19 diagnostics products. RNA Wrapr is a molecular transport medium for COVID-19 sample collection, developed as part of the COVID-19 response team from Indian Institute of Science.

Molecular Transport Media that inactivates the Coronavirus immediately. Not only that! Azooka's RNA Wrapr does not require dry ice for storage and can be processed until a week. A storage medium for COVID-19 that is safe, easy to use and affordable. (RNA Wrapr comes in 3ml or 10ml vials with Fluccoluated Nylon Nasal Swabs. Price starts at INR 99 per vial.)

RNA Wrapr inactivates the virus immediately only preserving DNA/RNA content required for RT-PCR tests. The sample tubes can be stored up to 7 days in Room Temperature and transported without dry ice or gel packs. RNA Wrapr is safe to handle even during unexpected accidental spillage or handling errors. Developing countries can collect samples in centers without BSL2 or BSL3 certifications.

Azooka's RNA Wrapr is priced at INR 99 in India, aligned with the price of one litre of petrol, to help the diagnostic centers upgrade from VTM to MTM. Azooka plans to enter the APAC market through partners with $9 and $6 pricing plans per test.

"Azooka has actively been a part of the fight against COVID by developing PCR and RT PCR kits with support from Dept of Biotechnology and Elevate Karnataka even before the pandemic hit us," quoted Alex D Paul, CEO, Azooka Labs. He further added, "MTM has ensured safety and security of COVID-19 samples to be stored at Room Temperature for up to seven days".

"Azooka is the only startup from India working to replace Carcinogenic and Mutagenic SYBR dyes widely used in RUO and Diagnostics reagents. Safety and cost savings needed for COVID crisis management today are the highlights of Azooka's MTM," says Dr. C V Natraj, former SVP, Corporate Research, Unilever plc.

"Azooka is striving to provide a safer molecular grade transport medium that is at sub Rs. 100. We are appealing to a segment of users, who care about the safety of their frontline health care workers," stated Dr. Fatima Benazir, Co-founder & CSO, Azooka Labs.

About Azooka Labs
Azooka is a patented fluorophore company focused on developing safe biotech consumables at a price affordable for all countries across the globe. Azooka's first diagnostics product RNA Wrapr- molecular transport medium, is approved by ICMR and certified by CE. Azooka is an IISc invested startup based in Bengaluru with R&D unit at the Indian Institute of Science and manufacturing facility in Peenya Industrial Area, Karnataka.

Azooka was recently awarded the 'Best Women-Led Enterprise' at StartUp India 2020. Azooka is open for licensing and partnerships worldwide. Governments and Health Organizations can directly contact Azooka for COVID-19 Crisis Management. For more information visit: http://azooka.life/ and for the prices visit: https://azooka.life/rna-wrapr-molecular-transport-medium/

Media Contact:
Alex D Paul, CEO
+91-9108424562
alx@azooka.life

Topic: Press release summary
Source: Azooka Labs

Sectors: BioTech, Healthcare & Pharm
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Latest Press Releases
HKTDC 4Q25 Export Confidence Index: 2026 Hong Kong Export Growth of 8-9%, Sustained AI product demand lays solid foundation for future expansion  
Friday, December 12, 2025 10:15:00 PM
Everest Medicines Announces Commercialization Service Agreement and License Agreement with Hasten  
Dec 12, 2025 14:35 HKT/SGT
Anime Tokyo Station: A Series of Linked Events to Be Held in Conjunction with the Anniversary Joint Exhibition  
Friday, December 12, 2025 10:00:00 AM
CMS (867/8A8): NDA of Innovative Drug Y-3 for Injection for Acute Ischemic Stroke Accepted in China  
Dec 11, 2025 20:00 HKT/SGT
Focus Graphite Achieves 99.9996 wt.% Ultra-High Purity and 2.03 ppm EBC in Follow-On Testing  
Dec 11, 2025 18:09 HKT/SGT
Nasdaq Verafin Joins Global Anti-Scam Alliance  
Dec 11, 2025 14:21 HKT/SGT
Dr. Teck Lim Chia, Chairman and CEO of CBL International, Honored at the Prestigious Directors of the Year Awards  
Dec 11, 2025 12:54 HKT/SGT
Cloudbreak Pharma Soars 80%+ on Multiple Catalysts, Driving Value Re-Rating  
Dec 11, 2025 08:20 HKT/SGT
Indonesian Government's Swift Response in Recovering Flood-hit Sumatra  
Dec 10, 2025 23:30 HKT/SGT
TIS Helps Treasury Teams Navigate the Ongoing ISO 20022 Transition After the 2025 Banking Deadline  
Dec 10, 2025 21:00 HKT/SGT
More Press release >>
 Events:
More events >>
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575